Brief: Vir Biotechnology Announces First Patient Dosed In Part 3 Of Phase 1 Trial
09/10/2025 22:06
Oct 9 (Reuters) - Vir Biotechnology Inc VIR.O: VIR BIOTECHNOLOGY ANNOUNCES FIRST PATIENT DOSED IN PART 3 OF PHASE 1 TRIAL OF PSMA-TARGETING PRO-XTEN® DUAL-MASKED T-CELL ENGAGER VIR-5500 IN COMBINATION WITH ANDROGEN RECEPTOR PATHWAY INHIBITORS FOR THE TREATMENT OF METASTATIC PROSTATE CANCER Source text: ID:nBw6np3xTa Further company coverage: VIR.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO